Nuvation Bio Inc. Class A

Stage 3 · Topping · week 3

As of Oct 22, 2026, Nuvation Bio is in Stage 3, the topping phase, now in week 3 (since Oct 6, 2026). It closed at $4.70, 50.7% below its 52-week high and below its 200-day average, which is falling.

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. More about the company

$4.70

-3.69% today

$1.7B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is NUVB early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 15w

S2 19w

S4 14w

S1 15w

S2 24w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S1 3w → S4 15w → S1 8w → S2 19w → S3 2w → S2 10w → S3 4w → S4 7w → S1 8w → S4 14w → S1 15w → S2 24w → S3 10w → S4 6w → S1 9w → S2 8w → S3 2w current

Total tracked: 166 weeks across 17 stage runs.

NUVB among Biotechnology152nd of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…152	NUVBNuvation Bio Inc. Class A	Stage 3 · wk 3	63	−17.7%

vs 52W High

-50.7%

$4.05 lo$9.54 hi

50.7% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 3

1w13w26w

Week 3, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-14.3%

200 DMA: $5.48 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

1.08x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-17.7%

-26.8%

-6.7%

YTD

-45.2%

+11.6%

Scan Membership

Breakout Watch

Latest: 2024-07-11

3 appearances in last 60 days. First seen: 2021-06-11.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S3

Wk 3 · Vol 1.08x

2026-10-21S3

Wk 3 · Vol 0.72x

2026-10-20S3

Wk 3 · Vol 1.28x

2026-10-19S3

Wk 2 · Vol 0.79x

2026-10-16S3

Wk 2 · Vol 0.82x

2026-10-15S3

Wk 2 · Vol 0.88x

2026-10-14S3

Wk 2 · Vol 0.69x

2026-10-13S3

Wk 2 · Vol 1.40x

2026-10-12S3

Wk 1 · Vol 0.58x

2026-10-09S3

Wk 1 · Vol 0.54x

2026-10-08S3

Wk 1 · Vol 1.70x

2026-10-07S3

Wk 1 · Vol 1.00x

Moving averages & range

50 DMA

$5.88

200 DMA

$5.48

52W High

$9.54

52W Low

$4.05

5D Low

$4.45

Resistance levels (recent highs)

20d High

$5.74

60d High

$7.26

120d High

$7.26

250d High

$9.54

Next resistance

+22.1%

to 20d High

ROE

-47.8%

Profit margin -88.2%

Dividend Yield

0.00%

P/B 6.5

Nuvation Bio: quick answers

What stage is Nuvation Bio in?

As of Oct 22, 2026, Nuvation Bio (NUVB) is in Stage 3, the topping phase. It entered Stage 3 on Oct 6, 2026 and is in week 3. What the four stages mean

Is Nuvation Bio in an uptrend?

Its uptrend has stalled. Nuvation Bio is in Stage 3, the topping phase that follows an advance. It trades 14.3% below its 200-day average, which is falling.

How far is Nuvation Bio from its 52-week high?

Nuvation Bio closed at $4.70 on Oct 22, 2026, 50.7% below its 52-week high of $9.54. Its 52-week low is $4.05.

How has Nuvation Bio performed over the past year?

As of Oct 22, 2026, Nuvation Bio is up 11.6% over the past year and down 45.2% so far in 2026.

Which sector and industry is Nuvation Bio in?

Nuvation Bio is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.